Literature DB >> 32313979

Radiological imaging in multiple myeloma: review of the state-of-the-art.

Francesca Di Giuliano1, Eliseo Picchi2,3, Massimo Muto4,5, Antonello Calcagni6,7, Valentina Ferrazzoli1, Valerio Da Ros7,8, Silvia Minosse7, Agostino Chiaravalloti7,9, Francesco Garaci1,10, Roberto Floris6,7, Mario Muto5.   

Abstract

PURPOSE: Multiple myeloma is a type of blood cancer arising from the uncontrolled clonal proliferation of malignant plasma cells resulting in impaired hematopoiesis, hyper production of monoclonal protein, bone tissue destruction leading and renal system alterations up to kidney failure. The aim is to review the state-of-the-art of radiological imaging in multiple myeloma.
METHODS: Radiological techniques as well as the advancements in imaging technology have been reviewed and summarized. The main radiological findings of different imaging techniques in patients suffering from multiple myeloma are also illustrated.
RESULTS: Different radiological techniques provide structural and functional data. In the last years, conventional skeletal survey has gradually lost its utility and it has been replaced by whole body low-dose computed tomography which allows to identify also small lytic lesions, the medullary and the extramedullary involvement. Nowadays, magnetic resonance is the most sensitive imaging technique for detecting of skeletal as well as medullary involvement in patients with multiple myeloma. Thanks to the multiparametric evaluation (morphological, diffusion weighted and perfusion imaging sequences) and to the quantitative analysis, magnetic resonance imaging is proved to be useful in the early evaluation of response to therapy. Finally, positron emission tomography has greater sensibility compared to computed tomography as it provides quantitative data; however, the lower expression levels of the specific gene involved in the glycolysis pathway are associated with false-negative results with consequent underestimation of the disease.
CONCLUSION: The only use of the advanced combined multimodal imaging allows a better evaluation, staging and early assessment of treatment response in patients with multiple myeloma.

Entities:  

Keywords:  CT; Interventional radiology; MRI; Multiple myeloma; PET

Mesh:

Year:  2020        PMID: 32313979     DOI: 10.1007/s00234-020-02417-9

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  5 in total

1.  Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT.

Authors:  S C Brandelik; S Skornitzke; T Mokry; S Sauer; W Stiller; J Nattenmüller; H U Kauczor; T F Weber; T D Do
Journal:  Eur Radiol       Date:  2021-03-30       Impact factor: 5.315

2.  Ultra-Low-Dose Whole-Body Computed Tomography Protocol Optimization for Patients With Plasma Cell Disorders: Diagnostic Accuracy and Effective Dose Analysis From a Reference Center.

Authors:  Davide Tore; Osvaldo Rampado; Carla Guarnaccia; Roberto Mina; Maria Oronzio; Ambra Santonocito; Alessandro Serafini; Giulio Antonino Strazzarino; Laura Gianusso; Sara Bringhen; Paolo Fonio; Alessandro Depaoli
Journal:  Front Oncol       Date:  2021-11-17       Impact factor: 6.244

Review 3.  Imaging for Plasma Cell Dyscrasias: What, When, and How?

Authors:  Amrita Guha; Antariksh Vijan; Ujjwal Agarwal; Jayant Sastri Goda; Abhishek Mahajan; Nitin Shetty; Navin Khattry
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

Review 4.  Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging.

Authors:  Karla M Treitl; Jens Ricke; Andrea Baur-Melnyk
Journal:  Skeletal Radiol       Date:  2021-05-24       Impact factor: 2.199

Review 5.  Spinal vascular lesions: anatomy, imaging techniques and treatment.

Authors:  Valerio Da Ros; Eliseo Picchi; Valentina Ferrazzoli; Tommaso Schirinzi; Federico Sabuzi; Piergiorgio Grillo; Massimo Muto; Francesco Garaci; Mario Muto; Francesca Di Giuliano
Journal:  Eur J Radiol Open       Date:  2021-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.